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1. Introduction 
The application of embryonic stem (ES) cells to research and therapy has been a landmark 
development in science. Cell therapy using ES cells depends on the progress of the stable 
culture conditions and differentiation induction methods. ES cells were first obtained 
directly from inner cell masses (ICMs) of blastocysts by Evans and Kaufman (1981), and 
Martin (1981). These cells can self renew to produce stem cell itself and repopulate into 
many different tissues, including the somatic- and germ-cell lineages in chimeras (Bradley et 
al., 1984). After developing the methods for establishing the ES (mES) cell lines of mice, ES 
cell lines of other species including primates and human were also established (Thomson et 
al., 1995, 1998). Although ES cells can be obtained from 8-cell stage embryos or morula, they 
are more easily obtained from blastocyst stage embryos (Delhaise et al., 1996; Strelchenko et 
al., 2004). Now the sources of ES cells have been extended to include epiblast cells (Nichols 
and Smith, 2011) (Fig. 1). 
 
 
Fig. 1. The origins of embryonic stem cell. A, blastomeres of 8-cell and morula stage 
embryos; B, inner cell mass of blastocyst; C, epiblast cells of implanting embryo. 
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2. Human and mouse embryonic stem cells 
2.1 Mouse embryonic stem cell 
mES cells have been used mainly in the generation of mutant mice and in investigating 
cellular differentiation and the physiological role of genes during embryogenesis and 
development. These things can be accomplished through gene targeting and transmission of 
the acquired characters. Transmission of foreign genes to the next generation can be 
accomplished with incorporation of foreign genes into the germ cell-lineage (Bradley et al., 
1984; Wang et al., 1996). Specific gene deficient mice can be developed by manipulation of 
the genes in ES cells and introduce of ES cells into ICM (Hooper et al., 1987; Kuehn et al., 
1987; Wang et al., 1996). Mutations targeting specific genes by homologous recombination in 
ES cells have been designed and initially achieved using hypoxanthine-guanine 
phosphoribosyl transferase (HPRT) (Doetschmann et al., 1987). Germ line transmission of a 
targeted mutation in a gene other than HPRT was first obtained with c-abl (Schwartzberg et 
al., 1989) and 2-microglobulin (Zijlstra et al., 1989). To date, several hundred genes have 
been disrupted by homologous recombination in ES cells. The application of these 
techniques provided a way to evaluate the physiological roles of specific genes in ontogeny. 
In addition, conditional knockout mice are developed using ES cells and are used to analyze 
gene functions in a specific tissue or developmental stage. These approaches have provided 
much novel information and several important tools to study human development 
including ES cell therapies. 
2.2 Early data from embryonic carcinoma cells 
Human ES (hES) cells have become a key word in basic sciences and applied sciences. 
Before the optimal conditions were established for ES cell cultures, most of the basic 
knowledge about ES cells came from studies on embryonic carcinoma (EC) cells (Jakob, 
1984; Rossant and Papaioannou, 1984; Smolich and Papkoff, 1994). The first human EC cell 
line was established in vitro in 1985 (Sekiya et al., 1985). EC cells can spontaneously 
differentiate into somatic cells, germ cells and extraembryonic cells (Zákány et al. 1984), and 
have self-renewal ability (Andrews, 1987; Rosenstraus et al., 1984). During differentiation of 
EC cells into other cell types, proliferation is prerequisite, and apoptosis of EC cell 
derivatives accompany this process (Azizi et al., 2010; Mummery et al., 1984). After starting 
differentiation, the expression levels of some genes are determined at the levels of 
transcription and translation. In 1984, Schindler and Sherman reported the profile of protein 
and mRNA expression in murine EC cells, and the expression patterns of specific genes 
were explored during differentiation of EC cells (Scott et al., 1984; Silvan et al., 2009). 
Additionally, studies on proteins and carbohydrates have been performed to characterize 
the EC cells and their induced descendants (Amano et al., 2010; Andrews et al., 1984; 
Jemmerson et al., 1985). The role of the extracellular matrix is also examined during 
differentiation induction of EC cells (Grabel, 1984; Wartiiovaara et al., 1984) as the 
karyoplasm in EC cell gene expression (Gautsch, 1982). Differentiation induction of EC cells 
has been successful with various substances, such as retinoic acid, dibutyryl cyclic AMP 
(Jones-Villeneuve et al., 1983; Muramatsu and Muramatsu, 1983), dimethyl sulfoxide 
(Edwards et al., 1983) and coculture with specific cell types (Allin, 1984). Bell et al (1984) 
used growth factors to induce EC cell differentiation in target tissues.   
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2.3 Stemness and the differentiation of embryonic stem cells 
Although ES cells share some characteristics with EC cells, they have important differences 
(Chamber and Smith, 2004). The in vitro developmental potency and differentiation of ES 
cells have been studied since the mid-1980s. The developmental potency of ES cells was 
studied in vitro by Doetschman et al (1985). Additionally, the pluripotency and the 
characteristics of ES cells in vitro were analyzed in depth. ES cells lack differentiation-
inhibitory activity (DIA) unlike cells of cell lines, and they can differentiate into a wide 
variety of cell types. ES cells have an apparently normal diploid karyotype during long-term 
culture, can extensively colonize embryos without causing tumors or developmental 
anomalies, and can form normal gametes when differentiated into the germ line (Kaufman 
et al., 1983; Martin, 1981; Suda et al., 1987). The purified and cloned myeloid leukemia 
inhibitory factor (LIF) can exhibit DIA in the maintenance of competent mES cell lines 
(Smith et al., 1988; Williams et al., 1988). However, the requirement for maintaining 
stemness varies with the source of the ES cells. Primate ES cells stay in an undifferentiated 
state when grown on embryonic fibroblast feeder layers but differentiate or die in the 
absence of feeder cells, despite the presence of recombinant leukemia inhibitory factor 
(Thomson et al., 1995).  
Studies on the differentiation of stem cells during organogenesis have a long history (Ruch, 
1967). ES cell differentiation in vitro is controlled by exogenous factors, particularly 
paracrine factors (Heath and Smith, 1986; Spence et al., 2010). Various cell types can be 
induced from embryoid bodies using paracrine factors (Risau et al., 1988). During 
differentiation induction, various genes, such as genes of transcription factors, are up-
regulated or down-regulated (Dyson et al., 1989). The up-regulated transcription factors 
trigger a series of gene expression changes for the formation of a specific cell type (Kopp et 
al., 2008). 
3. Potency of embryonic stem cell in clinic 
3.1 Sources of human embryonic stem cells 
Through the accumulating knowledge on pluripotency and on the control of cellular 
differentiation, a fundamental understanding of developmental biology at the cellular and 
molecular levels has been expanded. It represents a gateway to major future clinical 
applications of these principles. The levels of transcription factors including nuclear 
receptors in ES cells are critical in the maintenance of stemness or differentiation of ES cells 
(Jeong and Mangelsdorf, 2009; Redshaw and Strain, 2010). Certain nuclear receptors are 
involved in the maintenance of ES cells in cooperation with Oct3/4, Nanog and Klf4 upon 
exogenous signals. Liver receptor homolog 1 (LRH1) and estrogen-related receptor beta 
(ERR) have functional roles in the maintenance of stemness of ES cells. On the other hand, 
germ cell nuclear factor (GCNF) and retinoic acid receptors (RARs) promote ES cell 
differentiation (Jeong and Mangelsdorf, 2009). The Sall gene family that encodes a group of 
developmental transcription factors controls the embryonic development and is also 
involved in the determination of ES cell fate. Sall1 knockout mice die perinatally with 
kidney dysgenesis or agenesis. Sall3 knockout mice have plate deficiency and abnormalities 
in cranial nerves. Sall4 mutation causes Acro-renal-ocular syndrome and Duane-radial ray 
syndrome. Sall4 also plays a role in the maintenance of stemness of ES cells through 
controlling its own expression and the expression of OCT4 (Yang et al., 2010). Identifying 
such switching molecules that regulate ES cell self-renewal versus differentiation can 
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provide insights into the nature of the ES cell (Navarro et al., 2010). Chromatin methylation 
is one example of how an epigenetic modification can modulate ES cell fate (Christophersen 
and Helin, 2010). 
In the late of 1990s the possibility of using ES cells for medicine was suggested (Gearhart, 
1998). The use of stem cells in regenerative medicine already has a long history, for example, 
in bone marrow transplantation and skin grafting. With the establishment of human 
embryonic stem (hES) cell lines, future clinical applications based on their developmental 
and regenerative abilities will become possible. hES cells were first established in 1998 by 
Thomson and colleagues. As in primate ES cells, the feeder layer seems essential for 
maintaining the hES cell lines. It is suggested that TGF-beta and myofibroblasts can support 
the propagation of hES cells in vitro (Kumar et al., 2010). 
Previously, the source of hES cells was restricted to morula and blastocysts but this is no 
longer the case. In 2006, induced pluripotent stem (iPS) cells were generated from mouse 
embryonic or adult fibroblasts by the retrovirus-mediated introduction of four transcription 
factors, Oct3/4, sox2, c-Myc, and Klf4 (Takahashi and Yamanaka, 2006). In 2007, iPS cells 
were established from human fibroblasts via introduction by the same four factors 
(Takahashi et al., 2007), and by using a slightly different combination of genes (Yu et al., 
2007). Human iPS cells are similar to human ES cells in many aspects, e.g., morphology and 
proliferation ability. Furthermore, mouse iPS cells are competent for adult chimeric mice 
and germline transmission. Growth potential, gene expression patterns, and the epigenetic 
status of iPS cells are similar to those observed in hES cells. iPS cells can differentiate into all 
three germ layers through embryoid bodies and to teratomas. In addition, they have been 
differentiated directly into neurons, beating cardiomyocytes in vitro (Carvajal-Vergara et al., 
2010) and others (Liu et al., 2011).  
3.2 Applied developmental biology 
A fertilized mammalian oocyte is totipotent and develops into the fetus and placenta 
concurrently losing its totipotency. During cleavage, the transition from maternal to 
embryonic genome activation encompassed in early stage embryos and cleaving embryos 
can gain the competence to become blastocysts (Hamatani et al., 2004). The competency to 
accomplish implantation and further development is gained during the periimplantation 
stages. For that process, the epithelium like structure, trophectoderm is formed and interacts 
with the epithelium of the uterine endometrium. On the other hand, the cells isolated within 
the blastoceol become inner cell mass (ICM) (Johnson and Mcconnell, 2004). ICM is a mass 
of cells having pluripotency and its cells can differentiate into all cell types of adult and 
extraembryonic membranes (Fernanez-Tresquerres et al., 2010). In specific in vitro 
conditions, ICM cells can keep their potency and maintain their proliferation ability 
(Yamanakaet al., 2006).  
Grouped cell movement and sequential spatio-temporal expressions of gene sets was 
observed after implantation. As a consequence of gastrulation, the embryos have three germ 
layers, endoderm, mesoderm and ectoderm (Hassoun et al., 2010; Luxardi et al., 2010). This 
process is accomplished with the forming of the axis (Rocha et al., 2010). For example, 
Med12, a large protein complex of 30 subunits interacting with transcription factors, is 
essential in correct Wnt/-catenin and Wnt/planar cell polarity signaling (Rocha et al., 2010; 
Taatjes et al., 2004). 
Most cells of embryos are eventually committed through triggering to a particular 
developmental pathway from which they rarely depart (Belting et al., 2004). Cell 
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determination is a stepwise process, and that full determination is preceded by a state of 
bias. This bias is either conformed or modified through cell interactions later in 
development. It is accomplished through community effect, lateral inhibition among 
equivalent cells, and embryonic induction which is the interaction between nonequivalent 
cells (Artavanis-Tsakonas et al., 1999). The determined state is almost stably passed on 
during mitosis. These are matched with the default progression and/or induced 
progression.  
A specific type cell is derived from a preexisting progenitor or stem cell for the specific area 
(Belting et al., 2004; Frieberg, 1996).  Designed modification of a group of ES cells to a 
specific cell type is mostly achieved by step by step induction through morphogens or 
intracellular signaling molecules as shown during organogenesis (Osakada and Takahashi, 
2011). The accumulation of knowledge regarding tissue genesis and organogenesis during 
gastrulation will give rise to the accomplishment of goals across other fields.  
The revolutionary advances in developmental biology have extended the utility of ES cells 
to both therapy and industry. As applied to the study of developmental biology (Lehtonen 
et al., 1989), the stemness and developmental potency of ES cells can be applied to various 
fields of medicine (Gearhart, 1998; Saxena et al., 2010). Thus far, stem cell biology has 
focused on identifying novel pathways such as those that maintain pluripotency and induce 
specific cell types. However, to date, it is not yet feasible to use ES cells in medicine or to 
strictly control their differentiation to a specific cell type in humans. To readily apply ES 
cells in therapy or other industries, the improvement of efficient protocols to direct stem cell 
differentiation into well-defined lineages is critical (Heng et al., 2004). 
4. Approaches to modulate embryonic stem cell properties 
To obtain a specific cell type, it is critical to understand the interactions of multiple genes 
and the associated factors that are involved in the differentiation and de-differentiation of 
ES cells. When we use inducers to generate a specific cell type from the embryoid body (EB) 
or directly from ES cells, it is difficult to generate single cell types at one time (Lu et al., 2009; 
Park and Lee, 2007). As shown in gastrulation and organogenesis, most morphogens and 
inducers are secreted into the intercellular fluid and into induced concentration-dependent 
specific gene expressions in neighboring cells (Wolpert, 1978). Therefore, in most cases of 
induction by inducer, unexpected results can occur during the induction of a cell type from 
an ES cell or embryoid bodies (EBs). 
Selective activation of the gene sets is essential to get a unique function of a specific cell. One 
of the best ways to accomplish this is through the delivery of a construct which contains 
target genes and expression-control sequences (Ishizaka et al., 2002). Among them 
intracellular signaling mediators and transcription factors are key molecules to get a specific 
cell type and they are main target for differentiation induction. To meet these requirements, 
many experimental conditions and gene delivery systems have been used. However, ES 
cells cannot be translocated to high affinity variable regulators such as a molecule of DNA, 
RNA or proteins. To overcome this problem, various approaches have been developed. 
When we classified according to their characteristics, mediators are either chemical, 
physical, or viral. 
Induced pluripotent stem cell (iPS) is a good example of a cell type in which transgene 
delivery and induction by transcription factors has been successful (Meissner et al., 2007; 
Park et al., 2008). However, those strategies introduce changes in DNA sequences or 
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disorder in genomic equivalence. Moreover, viral systems are suspected to have life-
threatening effects of immunogenicity and carcinogenicity. In addition, the efficiency of 
gene transfer in hES cells is still poor compared with other cell lines (Cao et al., 2010; 
Wasungu and Hoekstra, 2006). 
For these reasons, many scientists hesitate to use these strategies in medicine and have 
searched for new ways to control ES cell differentiation. Functional protein is easily turned 
over in the cytoplasm and regulates the function of a cell without disturbing the genetic 
background. Therefore, if we develop an easy way of introducing the transcription factors, 
intracellular signaling molecules or drug molecules into ES cells, ES cells will become a safe 
medicine. 
4.1 Delivery of nucleotides in to ES cells 
Introduction of regulating DNA or RNA into ES cells can be mediated by chemicals. Leaped 
progress in chemical mediated method has led to successful expression-construct delivery. 
Chemical mediators include diethylaminoethyl-dextran (DEAE-D), calcium phosphate, 
cationic lipid (liposome), cationic polymer, polylysine, histone, chitosan and peptides. 
The delivery of DNA or RNA with calcium phosphate was developed by Graham and van 
der Eb (1973) and has become a common method (Marucci et al., 2011). The mixture of DNA 
construct, calcium ion and phosphate are presented to cells in culture and the cells import 
the mixture through endocytosis. DEAE-D was developed by Pagano and Vaheri in 1965 for 
enhancing the infectivity of poliovirus RNA for cell culture. DEAE-D is a polycation, and 
the mixture of DNA and DEAE-D is positively charged. It is known that the mixtures are 
transferred into cytoplasm through endocytosis. Cationic lipids for DNA-transfection 
procedures were developed in 1987 (Felgner et al., 1987) and have become one of the most 
common methods (Templeton et al., 1997). Cationic lipids form liposome and the surface of 
liposome is positively charged. Cationic polymers are a group of highly water-soluble 
molecules such as polyethyleneimine (PEI) and dendrimers (Boussif et al., 1995; Dunlap et 
al., 1997). There are several types of cationic polymers; linear (polylysine, spermine, and 
histone), branched (polyethyleneimine, dendrimers) and spherical (Chitosan) (Zhao et al., 
2006). Cationic polymer self-assemble with DNA and generate tortoidal or spherical 
particles (Tang and Szoka, 1997). Polyplexes are engulfed by cells. Cationic peptide carriers 
are a new development and are expected to have an important role in gene delivery in vivo 
and in vitro. The peptides bind with DNA through ionic interaction to the phosphate 
backbone and additional noncovalent bonds. The transport mechanisms are endosomolytic 
(Chen et al., 2001) or membrane-penetrating (Xia et al., 2001). This method is not commonly 
used to carry the DNA or RNA constructs but the modular design of proteins is a good 
method for gene delivery (Xavier et al., 2009).  
Among the chemical mediated methods, mostly cationic lipids are employed in ES cells 
(Liou et al., 2010; Ma et al., 2004). One of the merits of the cationic lipid methods is that it is 
simple to apply. Methods which are optimized to ES cells or EB are a developing field (Liou 
et al., 2010; Ma et al., 2004; Villa-Diaz et al., 2010). In the case of the other chemical 
mediators, the efficiency is quite low or inadaptable to ES cells (Hong et al., 2004). On the 
other hand, combined methods are developed in ES cells such as peptide-liposome 
(Torchilin et al., 2003) 
On the other hand, physical forces such as, pressure, sound, shock, wave, or electrical pulse 
are used to deliver constructs. The history of using physical methods for gene delivery is 
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relatively short. The good points of these methods are saving cost, reducing risk through the 
large amount of DNA, and standardizing the quantity and procedure of gene delivery. The 
restriction of physical delivery includes restriction of delivery into the nucleus and internal 
organs or tissues that are difficult to reach. The microinjection method is one widely used 
procedure to delivery DNA or RNA constructs directly into the cells. Using injection pipette 
the constructs are introduced into the cytosol or microorganells of the target cell and it 
makes it possible to study the complicated cellular processes, structure, and function. 
Usually direct DNA inoculation by conventional needle injection and hydrodynamics 
deliver the naked plasmid DNA into cells, tissues or organs in vivo. These are very 
restricted, so far (Davis et al., 1993; Zhang et al., 1999). The genetic shotgun was introduced 
for gene delivery in 1990 (Armaleo et al., 1990). In this protocol, microscopic tungsten 
spheres are used to deliver DNA or RNA constructs. This method has been used to transfect 
plants cells, muscle cells, and various cultured cells including epithelial cells, endothelial 
cells, and monocytes (Chou et al., 2004). Gene delivery using electroporation is the most 
versatile method and can be applied to a wide variety of cell types. A short-pulsed electric 
field can result in the cellular uptake of DNA. Ultrasound is another physical energy source 
to open the membrane. Using this energy, new gene delivery methods have been developed. 
It facilitates the transfer of DNA into cells and across tissues. Its efficiency is very high and 
intraturmoral injection of DNA followed by focused ultrasound increased the expression of 
the target gene (Watanabe et al., 2010). The polymer-encapsulated microsphere delivery 
system developed the DNA construct in a manner of controlled drug-delivery. It can deliver 
the constructs in a manner that has site-specificity, is nuclease-safe, and provides a sustained 
release of DNA without repeated administration (Little et al., 2004). Polymer-encapsulated 
microsphere delivery may be useful in therapy in vivo (Little et al., 2004). 
Among the physical force mediated transduction methods, electroporation has been used as 
a standard transfection method for mES cells because its efficiency is quite high (Ma et al., 
2004). However, its use has also been limited because the viability of the transfected cells is 
quite low (Matsuoka et al., 2007; Svingen et al., 2009). The other limit is that ES cells have to 
located in a spedific chamber to get treatment. However, with the progression of the 
electroporation system, it is possible to get a large fraction of transiently transfected cells 
with minimal loss of cell viability and pluripotency (Moore et al., 2010). The microinjection 
method, conventional needle injection, hydrodynamics deliver, genetic shotgun, ultrasound 
and polymer-encapsulated microsphere delivery systems are not yet commonplace and, 
although further research is needed, it is expected that physical mediators will be good tools 
for working with ES cells. 
Virus mediate foreign gene delivery is observed in nature. Viruses have host specificity and 
the efficiency of viral infection can be increased by higher titers while avoiding 
immunosurveillance by an infected host. Using those characteristics, viral genomes have 
been developed as gene-delivery vehicles, since the early 1980s (Berkner, 1988; Shimotohno 
and Temin, 1981). Viral vectors include the adenoviruses, adeno-associated viruses, herpes 
simplex viruses, baculoviruses, lentiviruses, retroviruses and alphaviruses (Robbins and 
Ghivizzani, 1998; Couto and High 2010). The characteristics of vectors are dependent on 
their origins. Varial mediated gene delivery is a powerful method used with ES cells. iPS 
cells are a good example of viral mediate gene delivery of functional DNA constructs 
(Meissner et al., 2007; Park et al., 2008). 
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4.2 Delivery of functional proteins 
DNA constructs are powerful mediators for induction of ES cell differentiation. However, 
genetic modification by exogenous DNA construct can cause unidentified side effects. The 
development of a safe and efficient differentiation controller is, therefore, an urgent 
requirement for the effective implementation of stem cells in therapy and industry. As an 
efficient differentiation controller, functional proteins such as signal transduction proteins 
and transcription factors are suggested, because they degrade rapidly in physiological 
condition and can maintain or modulate the cell types.  
The molecular size of the protein is huge compared with the amino acid and cannot freely 
pass the cell membrane or nuclear membrane. To deliver proteins, cationic lipids and 
cationic polymers also have been applied (Murthy et al., 2003; Verdurmen and Brock, 2011). 
However, their translocation efficiency is variable, depending on the cell type and the size 
and quality of the mixtures. Besides, the functional proteins cannot be translocated into the 
karyoplasms. Peptides are also a useful candidate for the translocation of peptides into 
cytoplasm but it also has limitations in medical or biological application. However, they 
have aroused great interest and have continuously progressed. 
Cell-penetrating peptides (CPPs) are synthesized peptides derived from various proteins. 
CPPs can transport small molecules, peptides and proteins in the form of recombinants and 
mixtures (Sawant and Torchilin, 2010). Some transcription factors have a domain with 
strongly basic heteropeptides, containing at least four arginines and lysines, which functions 
as a nuclear localization signal (Boulikas, 1994; Henkel et al., 1992). Drosophila transcription 
factor Antennapedia (Antp) also has the ability to translocate across the cell membranes 
(Balayssac et al., 2006). A mildly hydrophobic segment located approximately 30 residues 
downstream of the signal peptide is critical in membrane permeability in an E. coli protein 
(Nilsson et al., 1993). Those sequences interacting with lipid bilayers are called CPPs. They 
can carry functional cargo in the form of transcription factors or drugs (Lin et al., 1995). 
CPPs are also referred to as cell-permeable peptides, protein transducing domains (PTDs), 
or Trojan horse peptides. Thus far, the designed CPPs are more than two hundred including 
a galparan analog (Pooga et al., 1998), poly-arginine (Wadia and Dowdy, 2003), TAT-PTD, 
penetratin, buforin 2, transportan, transportan 10, MAP, pVec, R8, R11, KALA, K-FGF, PEP-
1, and Synb1 (Chugh et al., 2010; Dietz and Bähr, 2005; Pooga and Langel, 2005) (Table 1).  
CPPs are able to ferry much larger proteins, chemicals, DNA or RNA, directly into living 
cells (Dietz, 2010; Jung et al., 2007; Kwon et al., 2009). 
Applying CPPs to basic sciences, medicine and industry has been attempted. CPPs can 
translocate a specific protein into the cytoplasm in mixed form or recombinant protein form. 
Using a recombinant cell-permeable Cre protein (His-TAT-NLS-Cre), recombination can be 
efficiently induced in mES cell-derived cells. Fortunately, the permeable Cre protein has no 
overt side effects on proliferation and neural differentiation (Haupt et al., 2007). Yang and 
colleagues (2009) worked with a library of poly-(beta-amino ester) end-modified derivatives. 
These derivatives were developed and optimized for high transfer efficiency in hES cell-
derived cells, human adipose-derived stem cells (hADSCs) and human mesenchymal stem 
cells (hMSCs). In the presence of 10% serum, the transfer efficiency was 27  2% in hMSCs, 
24  3% in hADSCs and 56  11% in hSECds (Yang et al., 2009). Recently human iPS cells 
were successfully established with CPP-conjugated reprogramming proteins (Kim et al., 
2009). However, the importation efficiency was poor.  
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CPP Cys-CPP Sequence 
Numer of 
Class of CPP 
Lys Arg 
Tat-PTD GRKKRRQRRRPPQ 2 6 Cationic 
Penetratin (ATF) RQIKIWFQNRRMKWKK 4 3 Cationic 
M918 MVTVLFRRLRIRRASGPPRVRV 0 7 Cationic 
KALA 
WEAKLAKALAKALAKHLAKAL
AKALKACEA 
7 0 Cationic 
R7 RRRRRRR 0 7 Cationic 
R8 RRRRRRRR 0 8 Cationic 
R11 RRRRRRRRRRR 0 11 Cationic 
MAP KLALKLALKALKAALKLA 5 0 Amphipathic 
pEP-1 KETWWETWWTEWSQPKKKRKV 5 1 Amphipathic 
Buforin 2 TRSSRAGLQFPVGRVHRLLRK 1 5 Amphipathic 
Transportan 10 (P10) AGYLLGKINLKALAALAKKIL 4 0 Chimeric 
Transportan 
GWTLNSAGYLLGKbINLKALAAL
AKKIL 
4 0 Chimeric 
pVec LLIILRRRIRKQAHAHSK 2 4 Chimeric 
K-FGF AAVALLPAVLLALLAP 0 0 
Hydrophobi
c sequences 
3-S AAVALLPAVLLALLAP 0 0 Hydrophobi
c sequences 
SynB1 RGGRLSYSRRRFSTSTGR 0 6 
Antimicrobia
l sequence 
NLS ALWKTLLKKVLKAPKKKRKVC 8 1 
Antimicrobia
l sequence 
b: attachment of Cys(Npys) on the  
Table 1. Sequences and features of some cell-penetrating peptides 
To promote the transduction of functional proteins into cytoplasm and karyoplasms of ES 
cells, the transduction abilities of various types of CPPs have been analyzed in mES cells 
(Jung et al., 2007). In these studies, the effects of the site of the CPP and the His tag in 
functional recombinant protein were first analyzed. We chose two expression vectors, one 
with an N-terminal His tag (6xHis-tag) and the other with a C-terminal tag (Fig. 2). Buforin 2 
cannot mediate the translocation of conjugated EGFP into the cytoplasm of R1 mES cells 
whether the His tag is located N-terminally (Buforin 2-EGFP-N) or C-terminally (Buforin 2-
EGFP-C). In contrast, pEP-1-EGFP-N translocates into the cytoplasm of R1 ES cells but pEP-
1-EGFP-C does not. pEP-1-EGFP-C mainly localized at the plasma membrane. The 
translocational efficiency of a CPP depends on the amino acid sequence and the length of 
the CPP. Buforin 2 is a 21-residue peptide containing a +7 net charge 
(TRSSRAGLQFPVGRVHRLLRK) and is a membrane-permeabilizing antimicrobial peptide 
(Takeshima et al., 2003). Its structure is amphipathic, consisting of an N-terminal random 
coil region, an extended helical region, a hinge, and a C-terminal regular -helical region. 
The membrane permeability is dependent on the -helical content of the peptides (Park et 
al., 2000). Although it efficiently translocates into HeLa cells (Takeshima et al., 2003), it can-
not penetrate ES cells whether the 6xHis-tag is located N-terminally or C-terminally (Fig. 3). 
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In HeLa cells, buforin 2-mediated translocation of proteins is concentration-dependent but 
temperature-independent (Takeshima et al., 2003). pEP-1 is a 21-residue peptide with a +6 
net charge (KETWWETWWTEWSQPLKKRKV), and is a membrane-permeabilizing 
antimicrobial peptide and is amphipathic. pEP-1 can be translocated into cytoplasm and 
karyoplasms of R1 mES cells when the 6x His is located N-terminally (pEP-1-EGFP-N), as in 
COS-7 cells (Petrescu et al., 2009), but pEP-1-EGFP-C cannot penetrate the R1 cell membrane 
(Fig. 3) (Jung et al., 2007). The translocation of Buforin 2-EGFP-N, Buforin 2-EGFP-C, pEP-1-
EGF-N and pEP-1-EGF-C does not depend on their concentrations (Fig. 4) (Jung et al., 2007). 
Translocation into the cell by pEP-1 dose not depend on energy (Henriques et al., 2007). It is 
suggested that electrostatic interactions are most important in the pEP-1 membrane 
interactions (Henriques et al., 2007). Although both Buforin 2 and pEP-1 are amphipathic, 
their translocation effects in ES cells differ. Additionally, the penetration affinity of pEP-1 is 
changed by the 6xHis-tag. Based on these observations, it is suggested that the N-terminal 
location of His on pEP-1 is responsible for its cell-penetrating efficiency. Therefore, the 
penetration effects of CPPs in ES cells are different from other cell types, such as epithelial-
derived cell lines or stroma-derived cell lines (Jung et al., 2007; Petrescu et al., 2009; 
Takeshima et al., 2003). 
Although 6xHis-tag is important in the efficiency of pEP-1 penetration into ES cells, the best 
strategy to express functional proteins in cells is to use a vector with a C-terminal tag. Based 
on the previous analysis, R7, MAP, pVec, K-FGF and yPFY were chosen as CPP and 
analyzed for their ability to transport EGFP through the plasma membrane of ES cells. R7 is 
an arginine-rich peptide with a +7 net charge. pVec is an 18-amino-acid peptide with a +8 
net charge and is derived from the murine vascular endothelial-cadherin protein (Elmquist 
et al. 2010; Hällbrink et al., 2001). N-terminal hydrophobic part of pVEC is crucial for 
efficient cellular translocation (Elmquist et al., 2006). MAP (KLAL, model amphipathic  
 
 
Fig. 2. Constructs of recombinant EGFP, CPP-EGFP-N and Pep-1-EGFP-C. In this construct, 
we wanted to use 6xHis-tag for purify and identification. Because it is known that 6xHis-tag 
usually do not disturb the formation of 3-dimensional structure and function of gene 
products. It is possible that His has + charge and it can effect on the role of CPP. Therefore 
we tested the possible effects of 6x His on the ability of CPPs. 
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Fig. 3. Translocation of EGFP-N and -C (A-1 and A-2, respectively), Buforin 2-EGFP-N and -C 
(B-1 and B-2, respectively), and pEP-1-EGFP-N and -C (C-1 and C-2, respectively) into R1 mES 
cells 24 hr after treatment. In natural culture condition, EGFP could not pass the cell 
membrane and the R1 ES cell did not take it through endocytosis. Site of 6xHis-tad did not 
give effect on the Buforin-2 transduction ability in mES cells but it gave effect on the pEP-1 
transduction ability in mES cells.  
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Fig. 4. Efficiency of transfection depends on the kinds of but independent on the 
concentration of Buforin 2 and pEP-1-EGFPs.  
CPP-EGFPs were administered at various concentrations (1; 5g/ml, 2; 50 g/ml; 3; 500 
g/ml) and observed after 12 hr. Vehicle (A), EGFP (B) and EGFP (B-b), Buforin 2-EGFP (C), 
pEP-1-EGFP (D) was administered to R1 mES cells and detected using confocal microscopy. 
-a means the N terminal 6xHis-tag and –b means the C terminal 6xHis-Tag. 
peptide) is an amphipathic helical peptide with a +5 net charge (Hällbrink et al., 2001). A 
positive charge as well as helicity and amphipathicity are all required for efficient 
translocation (Wolf et al., 2006). K-FGF and yPFY have no net positive charge. In our 
laboratory, pET-20b(+)deXhoI modified of pET-20b was used to construct CPP-EGFPs. To 
get the recombinant CPP-EGFPs, BL21 E. coli were used and purified with Ni2+-affinity 
column (Qiagen). R1 mES cells were maintained in ES medium containing 1000 IU LIF.  R7-
EGFP-C, MAP-EGFP-C, pVec-EGFP-C, K-FGF-EGFP-C and yPFY-EGFP-C (each 10 ng/ml) 
were incubated with R1 mES cells for 6 hr in ES medium containing 10% fetal calf serum 
and then analyzed for translocation with confocal microscope. Propidium iodide was used 
to stain the nucleus. Interestingly, all of them were localized both to the cytoplasm and 
karyoplasms (Fig. 5) (Cheon et al., manuscript in preparation). Based on these results, it is 
suggested that all these carriers can be applied in ES cells.  
Recently, it was discovered that R7 mediates the translocation of functional proteins into the 
cytoplasm of stem cells (Jo et al., 2010). Short-form human ESRRB was cloned in R7-pET-
20b(+)deXhoI, and recombinant RT-ESRRB was purified in BL21(DE3)pLysS. R7-ESRRB-
6xHis successfully translocated into the cytoplasm and karyoplasm (Fig. 6), and increased 
the expression of OCT4, NANOG and SOX2 (Fig. 7).  
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Fig. 5. Translocation of CPP-eGFP into R1 ES cells. 
(A-F) mES cells were treated with 10ng/ml EGFP (A), R7-EGFP (B), yPFY-EGFP (C), MAP-
EGFP (D), K-FGF-EGFP (E), or pVec-EGFP (F) for 6 hr at 37C. After treatment, all cells were 
stained with propidium iodide. 1 is eGFP images and 2 is the merged images.  
 
Fig. 6. R7-hESRRB-His6 protein can penetrate the plasma membrane within 5 hr after 
treatment and are completely localized in the nucleus within 24 hr after treatment. 
(A-C) the cells were not treated with R7-hESRRB-His6 protein but were immunostained 
www.intechopen.com
 Embryonic Stem Cells – Basic Biology to Bioengineering 136 
with anti-His-Taq(6X) antibody; (D-F) the cells were immunostained with anti-His-Taq(6X) 
antibody 5 hours after treatment with R7-hESRRB-His6 protein; (G-I) the cells were 
immunostained with anti-His-Taq(6X) antibody 24 hours after treatment with R7-hESRRB-
His6 protein. Images were captured using a confocal microscope (Carl Zeiss LSM 510 
META, Zeiss, Jena, Germany) at ×1,000 magnification.  
 
 
Fig. 7. Treatment with R7-hESRRB-His6 protein for 8 days (192 hr) increases the expression 
of OCT4, NANOG and SOX2.  
A, real-time PCR for the expression of OCT4, NANOG and SOX2; B, agarose gel 
electrophoresis and EtBr staining after real-time PCR. Statistically significant differences 
between each group are denoted by different letters (P<0.05)  
4.3 Usage of nanobeads as carriers of functional proteins 
The amount of translocated functional protein is also an important factor in directing the 
induction of ES cells into specific cell types or maintaining ES cell stemness. In addition, the 
stability of the CPP-proteins is limited under physiological conditions. The translocation of 
CPP-proteins into cytoplasm can be inhibited by serum (Furuhata et al., 2006). Therefore, to 
control ES cell differentiation, it is necessary to regulate the amount of translocated 
functional protein. To prolong the lifespan of CPPs or CPP-conjugates, they have been 
modified but this approach has limits (Grunwald et al., 2009). 
Recently, nanoparticle techniques have been applied to medicine. Due to the physical and 
chemical characteristics of nanoparticles, they are more effective at targeting difficult-to-reach 
sites and have a better side effect profile. Hence, smaller doses of nanomedicines are needed to 
achieve the same therapeutic effect (Hock et al., 2011; Kuai et al., 2010; Neundorf, 2008). These 
advantages of nanoparticles as carriers are also evident in the study of ES cells. Poly(-amino 
esters) can fulfill the role of translocation mediator of a VEGF plasmid into hES cells (Yang et 
al. 2009). A chimeric protein, GFP-FRATtide, attached to a hydrophobically modified 15-nm 
silica nanoparticle is efficiently delivered to the cytosol of human embryonic kidney cells and 
rat neural stem cells (Shah et al., 2011). Tran and colleagues studied the effects of nanoparticles 
on morphological differentiation in mES cells (Tran et al., 2007). However, so far, the efficiency 
of this technique is not high in ES cell studies. 
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Another strategy to use nanoparticles is to apply the metabolic characteristics of ES cells and 
the characteristics of membranes to the nanoparticles. ES cells can use glucose and require 
glucose for further development. During the development of preimplantation embryos, the 
mammalian embryo needs a constant supply of energy substrates to remain viable. Usually, 
mammalian oocytes receive substrates, especially energy substrates, from the oviduct and 
uterus because they do not store much substrate in the cytoplasm during oogenesis. 
Glucose, lactate and pyruvate are essential components in preimplantation embryo culture 
media, and there are stage-specific preferences for them. Glucose may permit the expression 
of metabolic enzymes and transporters in compacting morula that are capable of generating 
the energy required for blastocyst formation. In addition, metabolites of glucose may be 
involved in cellular activity during the development of preimplantation embryos. 
Periimplantation embryos need glucose (Biggers and Summers, 2008). Therefore, ES cells 
can take up glucose as well as glycated proteins. Glucose-coated polymeric nanobeads have 
been prepared by dispersion polymerization (Jung et al., 2009). As a model protein, 
enhanced green fluorescent protein was ligated to the nanobeads and successfully 
translocated into mES cells (Fig. 8, Fig. 9). It is suggested that glucose-coated nanobeads 
could be a general cargo for the intracellular delivery of various macromolecules in ES cells.  
 
 
Fig. 8. Translocation experiments of the EGFP-ligated beads into R1 mouse embryonic stem 
cells. 
A, the confocal microscopic images. 1-a and 1-b, cells treated with EGFP alone; 2-a and 2-b, 
cells treated with non-coated beads; 3-a and 3-b, cells treated with 5%-glucose-coated beads; 
4-d and 4-m, cells treated with 10%-glucose-coated beads; 1-a, 2-a, 3-a, and 4-a are dark field 
images; 1-b, 2-b, 3-b, and 4-b are merged images (dark-bright fields). The merged images 
show that the cells are localized at the fluorescent regions. B, the relative intensities of the 
translocated EGFP. The intensities were measured using confocal microscopy (average ± SD; 
the measurements were repeated seven times and averaged).  
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Fig. 9. TEM photomicrograph of EGFP-ligated glucose beads in R1 mouse embryonic stem 
cells. Arrows indicate the translocated beads.  
In addition, these nanobeads could be more stable in the blood stream and tissue fluids 
compared than CPPs. On the other hand, if we add more functions in nanobeads, it can be 
carry a designed amount of functional protein. For example, shuttle signaling and self 
degradation can be helpful. To apply glucose nanobeads to in vitro and in vivo systems, 
further studies are needed, such as optimizing their homing and controlling the transporting 
amounts in karyoplasms and cytoplasm. 
5. Summary 
ES cells have been used to study the differentiation of various cell types and tissues in vitro, 
such as neural cells, hematopoietic lineages, cardiomyocytes, hepatocytes, -cells, and 
epithelium. In addition, ES-derived cells have been successfully transplanted into fetal and 
adult mice, where they have demonstrated morphological and functional integration 
(Kennedy et al., 1997). However, their use is still in the beginning stages in humans. It is 
difficult to translate laboratory advancements to human therapy because there are many 
obstacles to using ES cells in medicine (Piscaglia et al., 2010; Rossi et al., 2010). DNA 
construct mediated induction of ES cell-differentiation can cause unexpected side effects in 
the body. Therefore the best way is to use the functional proteins which regulate cellular 
characteristics such as transcription factors. Those factors can express their functional role, 
when they are located in proper sites, cytoplasm or karyoplasms. CPPs can be transported 
into cytoplasm and karyoplasms. 
This means that a membrane penetrating carrier is needed for the protein-application to get 
a specific cell type from ES cells. Based on this, CPP may be a clue to get such a goal. A 
nanobead which can easily translocate the cell membrane is also a clue to achieve such a 
goal. Although to apply the CPPs or specific nanoparticle-cargo in cell therapy using 
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protein, further studies are needed. These studies would open up new methods of therapy 
which are safe and economic. However, research on all aspects of ES cell biology will soon 
overcome these obstacles and make their use in therapy more safe and effective. 
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